These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12642031)

  • 1. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
    Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
    New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
    Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
    DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients.
    Re MC; Vignoli M; Furlini G; Gibellini D; Colangeli V; Vitone F; La Placa M
    J Clin Virol; 2001 Apr; 21(1):81-9. PubMed ID: 11255101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.
    Nicoli F; Chachage M; Clowes P; Bauer A; Kowour D; Ensoli B; Cafaro A; Maboko L; Hoelscher M; Gavioli R; Saathoff E; Geldmacher C
    BMC Infect Dis; 2016 Jul; 16():344. PubMed ID: 27450538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
    Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
    J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans.
    Senkaali D; Kebba A; Shafer LA; Campbell GR; Loret EP; Van Der Paal L; Grosskurth H; Yirrell D; Kaleebu P
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):587-94. PubMed ID: 18366309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.
    Rezza G; Fiorelli V; Dorrucci M; Ciccozzi M; Tripiciano A; Scoglio A; Collacchi B; Ruiz-Alvarez M; Giannetto C; Caputo A; Tomasoni L; Castelli F; Sciandra M; Sinicco A; Ensoli F; Buttò S; Ensoli B
    J Infect Dis; 2005 Apr; 191(8):1321-4. PubMed ID: 15776379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV regulatory and accessory proteins: new targets for vaccine development.
    Robert-Guroff M
    DNA Cell Biol; 2002 Sep; 21(9):597-8. PubMed ID: 12396601
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma.
    Demirhan I; Chandra A; Hasselmayer O; Biberfeld P; Chandra P
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):364-8. PubMed ID: 10634198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
    Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
    Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-immunization with an HIV-1 Tat transduction peptide-rotavirus enterotoxin fusion protein stimulates a Th1 mucosal immune response in mice.
    Kim TG; Befus N; Langridge WH
    Vaccine; 2004 Jan; 22(3-4):431-8. PubMed ID: 14670325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.
    Reiss P; de Wolf F; Kuiken CL; de Ronde A; Dekker J; Boucher CA; Debouck C; Lange JM; Goudsmit J
    J Acquir Immune Defic Syndr (1988); 1991; 4(2):165-72. PubMed ID: 1898969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.